End stage renal disease.
Hall
Yoshio
Y
Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA.
Chertow
Glenn
G
D000068256:Darbepoetin alfa; D015314:Dialysis Solutions; D004921:Erythropoietin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005936:Glucans / Q000627:therapeutic use; D005947:Glucose / Q000627:therapeutic use; D006801:Humans; D000077607:Icodextrin; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D010530:Peritoneal Dialysis; D011073:Polyamines / Q000627:therapeutic use; D006435:Renal Dialysis; D000069603:Sevelamer
D015314:Dialysis Solutions; D005936:Glucans; D011073:Polyamines; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000077607:Icodextrin; D000069603:Sevelamer; D005947:Glucose